Anavex Life Sciences Corp. (NasdaqGS: AVXL)
Health Care · Biotechnology · US
$3.24
+0.62% today · -65.5% 1Y
Anavex Life Sciences Corp. (NasdaqGS: AVXL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $300.26M and employs 34 people.
Over the last twelve months the share price has lost 65.5%, trading between 2.26 and 10.40.
Tweenvest scores Anavex Life Sciences Corp. across four factors: quality 32/100. Its strongest factor is quality.
AVXL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $300.26M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 1.14
- 52-week high
- $10.40
- 52-week low
- $2.26
- Avg volume (3M)
- —
- Shares outstanding
- 92.67M
- Employees
- 34
- Next earnings
- —
About Anavex Life Sciences Corp.
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
- ISIN
- US0327973006
- Founded
- 2004
- Listed since
- Aug 2, 2006
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.